Research Article
Ex Vivo Study of Laban's Role in Decreasing Hemolysis Crisis in G6PD-Deficient Patients
Table 1
Prevalence of G6PD deficiency levels and hemolysis of human blood cells treated with FBE and FBL.
| G6PD deficiency categorization | Prevalence of G6PD deficiency levels | Lysis (%) of human blood cells treated with FBE | Lysis (%) of human blood cells treated with FBL | Total samples tested 57 (100%) | — | |
| <10% (<0.64 U/gHb) | 0 | — | |
| 10–30% (0.64–1.92 U/gHb) | 21 (36.84%) | 70.74 ± 1.26%–90.65 ± 2.09% Mean: 82.06 ± 1.63% | 19.95 ± 0.95%–26.63 ± 0.68% Mean: 23.11 ± 0.76% |
| 30–60% (1.92–3.84 U/gHb) | 18 (31.57%) | 67.13 ± 1.65%–76.09 ± 1.96% Mean: 70.61 ± 1.36% | 9.68 ± 1.35%–21.48 ± 0.96% Mean: 14.13 ± 1.05% |
| >60% (>3.84 U/gHb) | 18 (31.57%) | 35.80 ± 2.06%–47.85 ± 1.05% Mean: 44.06 ± 1.49% | 1.21 ± 0.23%–9.71 ± 0.68% Mean: 5.75 ± 0.64% |
|
|